Shares of Pfizer Inc. closed lower on Thursday, March 12, 2026, declining 1.6% to finish the trading session at $26.86. The move came as part of a widespread selloff across U.S. equity markets, driven by rising oil prices amid escalating geopolitical tensions in the Middle East. The major market indices, including the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite, each fell more than 1.5% on the day.
Financial Forecast and COVID Headwinds
The pharmaceutical giant continues to manage a transition away from the peak revenue generated by its COVID-19 vaccine and therapeutic products. In December 2025, Pfizer provided its financial outlook for 2026, projecting adjusted earnings per share in the range of $2.80 to $3.00. The company anticipates revenue for the year to be between $59.5 billion and $62.5 billion. Notably, the profit forecast fell short of Wall Street analyst expectations at the time of its announcement.
Pipeline Developments and Competitive Landscape
Pfizer's research pipeline saw significant activity last week. Chinese regulatory authorities granted approval for Xianweiying, the company's GLP-1 receptor agonist medication for weight management. This class of drugs is renowned for its ability to suppress appetite and has become a highly competitive market segment.
In a separate development on Monday, March 9, Pfizer announced that its experimental eczema treatment, tilrekimig, successfully met its primary endpoint in a mid-stage clinical study. The positive results pave the way for the initiation of late-stage trials, which are slated to begin later this year. Analyst Evan Seigerman of BMO Capital Markets suggested the drug could potentially compete with Dupixent, the established eczema therapy marketed by Regeneron Pharmaceuticals and Sanofi, though he emphasized that comprehensive safety and placebo comparison data will be critical for evaluating its profile.
The competitive intensity in key therapeutic areas remains high. Rival Eli Lilly and Company announced plans on Wednesday for a substantial $3 billion investment in China over the next decade. The capital is intended to boost manufacturing capacity for orforglipron, Lilly's investigational oral medication targeting diabetes and obesity. This strategic move underscores the fierce competition and significant financial commitments companies are making in markets where Pfizer is also seeking a foothold.
Regulatory and Legal Environment
Vaccine policy discussions in the United States remain fluid. Reports on Wednesday indicated that U.S. vaccine advisers abandoned a plan to formally review challenges associated with mRNA-based COVID-19 shots. Earlier this month, Pfizer Chief Executive Officer Albert Bourla expressed concerns regarding leadership at the U.S. Food and Drug Administration's vaccine division, stating the current director was not adequately receptive to staff input.
On the legal front, Pfizer faced a setback this week. The company was unsuccessful in a bid to block a former prosecutor from participating in an ongoing generic-drug price-fixing litigation case.
Long-Term Strategy and Challenges
In its 2025 annual review released Thursday, CEO Albert Bourla highlighted productivity and margin improvements following a significant business restructuring. The company, according to earlier reports, is targeting 2028 for the initial approval of its own obesity drug and plans to advance more than 20 related clinical trials in 2026.
However, Pfizer's recovery narrative still confronts obstacles. Looking ahead to 2026, management's financial forecast incorporates approximately $5 billion in revenue from COVID-related products. Simultaneously, the company is preparing for a headwind of roughly $1.5 billion as several older medicines lose patent exclusivity and face new competition from generic alternatives.
In Thursday's market action, Eli Lilly shares closed down 2.3%, while Johnson & Johnson edged 0.4% lower. Despite the day's decline, Pfizer's stock price remained within 4% of its 52-week high of $27.94, which was reached on February 13, indicating the shares are holding near recent peak levels.
